glp-1 drugs news today World Health Organization recommends for obesity Half of GLP-1 users ditch
Description
Long-term safety data on microdosing is explicitly not available due to a lack of dedicated studies
And given that the oral versions of GLP-1s offer no significant pricing difference from injectables for employers, their availability doesn't necessarily make the economics more favorable for companies, Barner added
The mean weight loss associated with SGLT2-I in clinical trials averaged from 1.5 to 3 kg compared to placebo
Bramante, C
